MaxCyte, Inc.

MaxCyte, Inc.

MXCT ·

MaxCyte, Inc. (MXCT) is a Medical devices company in the Healthcare sector, listed on London Exchange. This page provides the complete earnings calendar, dividend schedule, and financial data for MaxCyte, Inc. in 2026. The next earnings report is expected on November 11, 2026.

Earnings calendar

Next earnings date

11 Nov 2026

In 82 days

EPS estimate

-0.08

Revenue estimate

7.0M

Past earnings

12 Aug 2026
EPS actual
-0.08 (+11.1%)
estimate -0.09
Revenue actual
7.3M (+11.8%)
estimate 6.5M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 May 2026
EPS actual
-0.04 (+47.2%)
estimate -0.08
Revenue actual
9.7M (+32.5%)
estimate 7.3M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
24 Mar 2026
EPS actual
—
estimate -0.08
Revenue actual
—
estimate 9.1M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
12 Nov 2025
EPS actual
-0.12 (-7.2%)
estimate -0.11
Revenue actual
6.8M (0.0%)
estimate 6.8M
Price reaction
1d
+2.37%
5d
-2.41%
30d
+4.37%
Sign in to view returns
Beat Miss usd

Latest earnings analysis

MaxCyte, Inc. beat consensus estimates in its latest earnings report, with EPS of $-0.08 coming in ahead of the $-0.09 estimate and revenue of $7.27 million exceeding estimates by 11.8%. In the prior quarter, both EPS and revenue also came in ahead of expectations.

Dividend calendar

No dividend history available.

EPS (Earnings Per Share)

Revenue

Company profile

MaxCyte, Inc. is a global life sciences enterprise dedicated to the identification, advancement, and commercialization of cutting-edge cell therapies. Its product portfolio encompasses a suite of ExPERT electroporation instruments: the ATx, designed for static electroporation in small to medium-scale cell transfection; the STx, a flow electroporation system facilitating protein creation, drug discovery, and the expression of therapeutic targets for cell-based analyses; the GTx, another flow electroporation solution, but tailored for extensive transfection in therapeutic contexts; and the VLx, engineered for exceptionally high-volume cell manipulation. Furthermore, the company supplies disposable processing assemblies (PAs) essential for cell processing and electroporation, alongside complementary accessories such as electroporation buffer solutions and software protocols. Founded in 1998, MaxCyte maintains its headquarters in Rockville, Maryland.

Sector
Healthcare
Industry
Medical devices
Country
United States
Exchange
London Exchange
CEO
Maher Masoud
Employees
114
IPO date
29 Mar 2016
ISIN
US57777K1060
Website
maxcyte.com

Frequently asked questions

When does MaxCyte, Inc. (MXCT) next report earnings?

MaxCyte, Inc. (MXCT) is scheduled to report earnings on November 11, 2026.

What was MaxCyte, Inc.'s most recent earnings date?

MaxCyte, Inc. (MXCT) last reported earnings on August 12, 2026.

Where is MaxCyte, Inc. stock listed?

MaxCyte, Inc. (MXCT) is listed on London Exchange.